30 Active Studies

Pancreatic Cancer Clinical Trials

Find actively recruiting research studies for pancreatic cancer. Connect with study sites near you and explore new treatment options.

30
Active Trials
96+
Locations
5,532
Participants Needed

Recruiting Studies

RecruitingNCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma ...

10 locations(Duarte, New Haven, Kissimmee)
740 participants
Daiichi Sankyo
View Study Details
RecruitingNCT05254171

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for me...

10 locations(Hot Springs, Fullerton, New Haven)
600 participants
Panbela Therapeutics, Inc.
View Study Details
RecruitingNCT01954992

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed ...

3 locations(Whittier, Tampa, Canton)
480 participants
Eleison Pharmaceuticals LLC.
View Study Details
RecruitingNCT04482309

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study...

10 locations(Burbank, Duarte, Fullerton)
468 participants
AstraZeneca
View Study Details
RecruitingNCT06079346

A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

The goal of this clinical study is to compare the efficacy and safety of OT-101 in combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX alone in patients with adva...

2 locations(Detroit, Houston)
455 participants
Oncotelic Inc.
View Study Details
RecruitingNCT06958328

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial ...

10 locations(Gilbert, Peoria, Phoenix)
356 participants
NRG Oncology
View Study Details
RecruitingNCT04340141

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed ...

10 locations(Birmingham, Fairhope, Mobile)
352 participants
Alliance for Clinical Trials in Oncology
View Study Details
RecruitingNCT06807437

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could beco...

10 locations(Birmingham, La Jolla, Los Angeles)
274 participants
SWOG Cancer Research Network
View Study Details
RecruitingNCT06051695

A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

The goal of this study is to test A2B694, an autologous logic-gated Tmodâ„¢ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell l...

10 locations(Gilbert, La Jolla, Los Angeles)
230 participants
A2 Biotherapeutics Inc.
View Study Details
RecruitingNCT03257033

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable....

10 locations(Loma Linda, Sacramento, Denver)
190 participants
RenovoRx
View Study Details
RecruitingNCT04858334

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (...

10 locations(Anchorage, Anchorage, Anchorage)
152 participants
National Cancer Institute (NCI)
View Study Details
RecruitingNCT06907043

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate r...

10 locations(Denver, Lake Mary, Boston)
130 participants
Eikon Therapeutics
View Study Details
RecruitingNCT04789486

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

This research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX), used in conjunction with MR-guided stere...

2 locations(Boston, Boston)
100 participants
Dana-Farber Cancer Institute
View Study Details
RecruitingNCT06115499

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

This phase II/III trial compares the effect of the 3-drug chemotherapy combination of nab-paclitaxel, gemcitabine, plus cisplatin versus the 2-drug chemotherapy combination of nab-paclitaxel plus gemc...

10 locations(Anchorage, Anchorage, Anchorage)
100 participants
Alliance for Clinical Trials in Oncology
View Study Details
RecruitingNCT04172532

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that h...

10 locations(Duarte, Irvine, Irvine)
98 participants
National Cancer Institute (NCI)
View Study Details
RecruitingNCT03682289

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

This phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants ...

3 locations(Duarte, San Francisco, Chicago)
89 participants
Rahul Aggarwal
View Study Details
RecruitingNCT04548752

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutati...

10 locations(Anchorage, Anchorage, Anchorage)
88 participants
National Cancer Institute (NCI)
View Study Details
RecruitingNCT04683315

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

This is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer....

2 locations(Scottsdale, Milwaukee)
87 participants
Medical College of Wisconsin
View Study Details
RecruitingNCT02843945

Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal....

6 locations(Tampa, Chicago, Oak Lawn)
80 participants
CivaTech Oncology
View Study Details
RecruitingNCT05249101

A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

This study is a Phase 1b/2, dose-escalation, randomized, multicenter study to assess the efficacy, safety, tolerability, and PK of ivaltinostat in combination with capecitabine and capecitabine monoth...

10 locations(Scottsdale, Newport Beach, San Francisco)
70 participants
CG Pharmaceuticals, Inc
View Study Details
RecruitingNCT06747845

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

The main goal of this study is to look at the effectiveness and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib and ipilimumab, on the patients and their pancreatic cancer....

2 locations(Boston, Philadelphia)
68 participants
Abramson Cancer Center at Penn Medicine
View Study Details
RecruitingNCT05988918

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

This protocol will enroll patients with pancreatic adenocarcinoma and adenosquamous carcinoma (Cohort 1), gastrointestinal/pancreatic neuroendocrine neoplasms with Ki-67 \> 20% (Cohort 2) and neuroend...

3 locations(Ann Arbor, Detroit, Madison)
66 participants
University of Michigan Rogel Cancer Center
View Study Details
RecruitingNCT02598349

Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas

The prognosis for patients with localized pancreatic adenocarcinoma who are not surgical candidates is poor. Patients characterized as having "borderline resectable" disease treated with preoperative ...

4 locations(Jacksonville, Warrenville, Flint)
60 participants
Proton Collaborative Group
View Study Details
RecruitingNCT06906562

A Phase II Nationwide, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreas Cancer With FGFR Genetic Alterations

This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distan...

8 locations(Birmingham, San Francisco, Miami)
40 participants
Sameek Roychowdhury
View Study Details
RecruitingNCT06168812

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer

The purpose of this study is to find out how effective and safe glipizide is for lowering blood sugar in people with pancreatic cancer....

7 locations(Basking Ridge, Middletown, Montvale)
40 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNCT05132504

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

Abbreviated Title: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Trial Phase: Phase II Clinical Indication: Pancreatic ductal ad...

3 locations(Houston, Houston, Houston)
30 participants
Baylor College of Medicine
View Study Details
RecruitingNCT05766748

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic pancreatic cancer....

6 locations(Los Angeles, Boca Raton, Eugene)
30 participants
Cantex Pharmaceuticals
View Study Details
RecruitingNCT06850623

Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer

The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer....

4 locations(Scottsdale, Detroit, Pittsburgh)
25 participants
EXACT Therapeutics AS
View Study Details
RecruitingNCT03652428

Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)

The purpose of this study is to determine the maximum tolerated dose of the chemotherapy drugs nab-paclitaxel and gemcitabine when combined with hypofractionated ablative proton therapy for the treatm...

2 locations(Washington D.C., Baltimore)
24 participants
University of Maryland, Baltimore
View Study Details
RecruitingNCT04543071

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

The purpose of this study is to determine if combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing the size of the tumor(s), if it will prolo...

3 locations(New York, Providence, Milwaukee)
10 participants
Gulam Manji
View Study Details

Frequently Asked Questions

What clinical trials are available for Pancreatic Cancer?

There are currently 30 actively recruiting clinical trials for pancreatic cancer. These studies are testing new treatments, therapies, and interventions at research sites across 96 cities.

How do I join a Pancreatic Cancer clinical trial?

To join a pancreatic cancer clinical trial: 1) Browse the available studies above, 2) Click on a study that interests you, 3) Complete the eligibility form, and 4) A study coordinator will contact you.

Are clinical trials free for patients?

Yes, clinical trial participation is free. In most studies, the treatment, medical tests, and doctor visits related to the trial are provided at no cost. Some studies may also compensate for time and travel.

Can I leave a clinical trial if I change my mind?

Yes, participation in any clinical trial is completely voluntary. You can withdraw at any time, for any reason, without affecting your regular medical care.